【摘要】 目的:探讨奥氮平单药治疗急性期精神分裂症患者血清白细胞介素-6(IL-6)水平变化及与疗效之间的关系。方法:检测106例急性期精神分裂症患者(患者组)和72名健康对照者(正常对照组)血清IL-6水平;患者组接受奥氮平单药治疗并随访12周,采用阳性与阴性症状量表(PANSS)评定治疗前后的精神症状。结果:共68例患者完成随访,脱落率为35. 8%。患者组与正常对照组基线期血清IL-6水平分别为(63. 89±4. 33) ng/L及(23. 84±2. 95) ng/L,两组间比较差异有统计学意义(F=3025. 82,P <0. 01)。患者组治疗12周血清IL-6水平(44. 17±6. 31) ng/L较基线期(63. 89±4. 33) ng/L明显下降(t=-23. 23,P <0. 01)。患者组治疗后PANSS评分中阳性症状分(F=682. 14)、阴性症状分(F=180. 27)、精神病理分(F=400. 36)和总分(F=570. 07)较基线期明显下降(P均<0. 01)。患者组血清IL-6水平变化与PANSS阴性因子分变化呈显著正相关(r=0. 26,P=0. 036),与阳性因子分(r=0. 22,P=0. 07)、精神病理分(r=-0. 01,P=0. 91)和总分(r=0. 18,P=0. 13)变化无显著相关。结论:奥氮平可能通过降低血清IL-6水平起到改善阴性症状的作用,血清IL-6水平可能是治疗阴性症状的潜在生物学标记物。更多还原

【Abstract】 Objective: To investigate the changes of serum interleukin-6 levels before and after olanzapine monotherapy in patients with acute schizophrenia and their relationship with therapeutic effects. Method:A total of 106 patients with acute schizophrenia and 72 healthy subjects were enrolled in the study. Patients were treated with olanzapine monotherapy and followed 12 weeks. Positive and negative syndrome scale(PANSS) was used to evaluate psychotic symptoms before and after treatment. Serum IL-6 levels were also measured.Results: 68 completed the 12-week follow-up study and dropout rate is 35. 8%. Serum IL-6 levels were(63. 89 ±4. 33) ng/L and(23. 84 ± 2. 95) ng/L in case and control groups,respectively. There was a significant difference between the groups(F = 3025. 82,P < 0. 01). A significant improvement in PANSS positive subscore(F =682. 14),negative subscore(F = 180. 27),general psychopathology(F = 400. 36) and total score(F =570. 07) were observed in case group(P < 0. 01),compared with those in baseline. Serum IL-6 levels before and after treatment in case group were(44. 17 ± 6. 31) ng/L Vs.(63. 89 ± 4. 33) ng/L,(t =-23. 23,P <0. 01). There was significant correlation of the change of IL-6 levels with the change of negative subscore(r =0. 26,P = 0. 036),but not with the changes of positive subscore(r = 0. 22,P = 0. 07),general psychopathology(r =-0. 01,P = 0. 91) and PANSS total scores(r = 0. 18,P = 0. 13). Conclusion: Olanzapine may improve negative symptoms through decreasing serum IL-6 levels. Serum IL-6 levels may be the biomarker for treating negative symptoms.更多还原